Clarivate Epidemiology's coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of NK/T-cell lymphoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the developed world.
Clarivate Epidemiology's NK/T-cell lymphoma forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with NK/T-cell lymphoma per year?
How will improvements in survival change the number of people diagnosed with NK/T-cell lymphoma per year?
Of all people diagnosed with NK/T-cell lymphoma, how many in higher-income countries are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NK/T-cell lymphoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least ten years of forecast data for the following NK/T-cell lymphoma patient populations:
CTCL diagnosed incident cases.
PTCL diagnosed incident cases.
CTCL diagnosed incident cases by subtypes.
PTCL diagnosed incident cases by subtypes.
CTCL diagnosed prevalent cases.
PTCL diagnosed prevalent cases.
First-line drug-treatable population subpopulation(s).
First-line treatment subpopulation(s).
Second-line drug-treatable population subpopulation(s).
Second-line treatment subpopulation(s).
Third-line drug-treatable population subpopulation(s).
Literature review (studies included in/excluded from the analyses of NK/T-cell lymphoma
Diagnosed incident cases
Diagnosed incident cases by stage distribution
Diagnosed prevalent cases
Drug-treatable and drug-treated populations
Risk / protective factors applied to disease forecast models
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.